{'Year': '2017', 'Month': 'May'}
Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients.
We characterized the pharmacogenomics (PGx) results received by diagnostic odyssey patients as secondary findings during clinical whole exome sequencing (WES) testing as a part of their care in Mayo Clinic's Individualized Medicine Clinic to determine the potential benefits and limitations to this cohort.